Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-10 | Douglas E. Giordano joined the Board in February 2017 in connection with the closing of the Company’s acquisition of Pfizer's Hospira Infusion Systems business. Mr. Giordano is Pfizer’s designated director. Mr. Giordano will not be compensated for his service on the Board. |
| 2018-04-05 | Douglas E. Giordano Mr. Giordano, 54, has been a director since February 2017. Mr. Giordano is Pfizer’s designated director. Mr. Giordano will not be compensated for his service on the Board. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22